OncoMatch/Clinical Trials/NCT05272826

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

Is NCT05272826 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Iberdomide and Bortezomib for multiple myeloma.

Phase 2RecruitingCanadian Myeloma Research GroupNCT05272826Data as of May 2026

Treatment: Iberdomide · Bortezomib · Dexamethasone · Isatuximab — This study will evaluate efficacy and tolerability of iberdomide, bortezomib, dexamethasone and isatuximab on demand administered in combination for newly diagnosed transplant-ineligible multiple myeloma patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: anti-myeloma therapy

Exception: does not include radiotherapy, bisphosphonates, or a single short course of steroid (≤ dexamethasone 40 mg/day for 4 days; not within 14 days of treatment start)

Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid [i.e. less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 14 days of treatment start])

Lab requirements

Blood counts

Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L; Platelet count ≥ 50 x 10^9/L; Hemoglobin ≥ 80 g/L

Kidney function

Creatinine clearance ≥ 30 mL/min either directly measured via 24-hour urine collection or calculated using MDRD

Liver function

Serum AST and ALT ≤ 1.5 x upper limit of normal (ULN)

Cardiac function

QTc interval < 470 msecs (QTcF); no evidence of current clinically significant uncontrolled arrhythmias; no history of MI, acute coronary syndromes, coronary angioplasty, stenting or bypass grafting within six months; no class III or IV heart failure (NYHA); no uncontrolled hypertension

Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L. Serum AST and ALT ≤ 1.5 x upper limit of normal (ULN). Creatinine clearance ≥ 30 mL/min...Platelet count ≥ 50 x 10^9/L...Hemoglobin ≥ 80 g/L...QTc interval ≥ 470 msecs...NYHA heart failure class III-IV...uncontrolled hypertension

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify